Tectonic Therapeutic (TECX) 2024 Wells Fargo Healthcare Conference summary

Company strategy and platform

• Focuses on developing biologics targeting GPCRs, an area with high drug discovery potential but few biologic options.

• Utilizes a proprietary platform to identify opportunities where biologics offer advantages over small molecules.

Lead program: TX-45 and clinical rationale

• TX-45 is based on relaxin biology, aiming to treat Group 2 pulmonary hypertension (PH) with preserved ejection fraction heart failure (HFpEF).

• Group 2 PH is a large, underserved market with no approved therapies and high mortality, especially in the CpcPH subset.

• TX-45 is designed to lower pulmonary pressures, improve left heart function, and remodel cardiac and vascular tissue.

• Differentiation from competitors includes longer half-life, potential for monthly dosing, and improved tissue penetration.

Clinical development and competitive landscape

• Phase 1b study is ongoing, targeting a 15–20% reduction in pulmonary vascular resistance and wedge pressure as key endpoints.

• Phase 2 will focus on HFpEF patients, enriching for CpcPH, with primary endpoint of pulmonary vascular resistance and secondary endpoints like six-minute walk test.

• Competitors (AstraZeneca, Lilly, Merck) are pursuing similar indications but with broader or different patient populations and endpoints.

• TX-45 may offer faster symptomatic relief and better safety profile compared to competitors like sotatercept.